Walgreens Boots Alliance (WBA) Expected to Announce Earnings on Thursday

Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) will likely be releasing its Q3 2025 earnings data before the market opens on Thursday, June 26th. Analysts expect Walgreens Boots Alliance to post earnings of $0.34 per share and revenue of $36.72 billion for the quarter.

Walgreens Boots Alliance (NASDAQ:WBA - Get Free Report) last posted its earnings results on Tuesday, April 8th. The pharmacy operator reported $0.63 EPS for the quarter, topping the consensus estimate of $0.53 by $0.10. The firm had revenue of $38.59 billion for the quarter, compared to analyst estimates of $37.90 billion. Walgreens Boots Alliance had a positive return on equity of 16.39% and a negative net margin of 3.80%. Walgreens Boots Alliance's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period last year, the company earned $1.20 earnings per share. On average, analysts expect Walgreens Boots Alliance to post $2 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Walgreens Boots Alliance Stock Performance

Walgreens Boots Alliance stock traded down $0.08 during midday trading on Friday, hitting $11.31. 13,457,678 shares of the company were exchanged, compared to its average volume of 20,749,296. The firm has a market capitalization of $9.79 billion, a PE ratio of -1.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.78. Walgreens Boots Alliance has a fifty-two week low of $8.08 and a fifty-two week high of $16.25. The business has a fifty day simple moving average of $11.16 and a two-hundred day simple moving average of $10.78. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.32 and a current ratio of 0.61.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on WBA shares. Wolfe Research raised shares of Walgreens Boots Alliance to a "hold" rating in a research note on Monday, February 24th. Wall Street Zen began coverage on Walgreens Boots Alliance in a research report on Wednesday, May 21st. They set a "hold" rating on the stock. Finally, Deutsche Bank Aktiengesellschaft cut Walgreens Boots Alliance from a "hold" rating to a "sell" rating and dropped their target price for the company from $11.00 to $9.00 in a research report on Friday, February 28th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $10.59.

Insider Buying and Selling

In other news, Chairman Stefano Pessina purchased 832,258 shares of the stock in a transaction dated Sunday, April 27th. The shares were purchased at an average cost of $11.01 per share, with a total value of $9,163,160.58. Following the completion of the purchase, the chairman now directly owns 145,621,079 shares of the company's stock, valued at approximately $1,603,288,079.79. The trade was a 0.57% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 17.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Walgreens Boots Alliance

An institutional investor recently bought a new position in Walgreens Boots Alliance stock. United Services Automobile Association purchased a new position in shares of Walgreens Boots Alliance, Inc. (NASDAQ:WBA - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,947 shares of the pharmacy operator's stock, valued at approximately $212,000. Institutional investors own 58.59% of the company's stock.

Walgreens Boots Alliance Company Profile

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.